top of page

Milestones & Achievements


  • Official launch of Spectrometer miniaturization project

2002 - 2007

  • Optical theory of miniature spectroscopic chips: Model establishment and theoretical verification.

  • The theory was recognized by the global optics community as the most difficult and challenging frontier problem to overcome.

2007 - 2012

  • Theoretical verification of miniature spectroscopic chip theory.

  • Initiation of the development of miniature spectroscopic chip manufacturing process.

2012 - 2018

  • Breakthrough in spectroscopic chip manufacturing process: Achieved high yield production.

  • Process precision: <1 nanometer, surpassing the current state-of-the-art semiconductor processes.

  • Spectrochip technology obtained multiple patents in the United States, China, and Taiwan.


  • SpectroChip Inc. was established.

  • Development and verification of the prototype of the SpectroChip color analysis instrument.

  • Obtained TFDA certification: Color analyzer, Clinical spectrophotometer and Immunoassay analyzer.


  • Conducted IRB research with major domestic hospitals, obtained actual clinical data verification, and achieved an accuracy rate of 99%.

  • Establishment of a database for 12 items of urine tests.


  • Prototype Release of the multi-functional analyzer, The ONE InstantCare.

  • Establishment of Covid-19 antibody testing database.


  • Collaboration with Kaohsiung Municipal Siaogang Hospital and Eternal Materials Co.,Ltd to form the "Medical Alliance".

  • Establishment of a Covid-19 neutralizing antibody testing database.

  • Cooperated with the University of Texas Medical Center to apply for EUA for clinical trials of Covid-19 neutralizing antibodies.


  • Launch of the Covid-19 corporate rapid screening project.

  • SpectroChip Enterprise Health Cloud Management platform went online.

  • The daily production capacity of the spectrochip increased to 100,000 pieces.

  • Establishment of databases for CK-MB and troponin I for cardiovascular disease detection and creatine and urine microprotein for kidney disease detection.

  • Development of a composite test kit for respiratory viruses FLU-A, FLU-B, and COVID-19.

  • Obtained the project manufacturing permit from the Ministry of Health and Welfare and the EDMA Code 15709008 permit from the European Union for COVID-19 SRBD antibody testing.


  • Collaboration with the Northern Medical Center in the United States for the Dengue fever testing big data research project.

  • Establishing a database for Dengue fever testing.

  • Collaboration with the Northern Medical Center for international precision medicine POCT projects.

  • Participation in the "Taiwan Precision Environmental Medicine Alliance" with Kaohsiung Municipal Siaogang Hospital and Kaohsiung Medical University.

  • Established the "Intelligent Medical Industry-Academia Alliance" with Kaohsiung Municipal Siaogang Hospital and Eternal Material.


  • FDA (510k)

  • Drug Vendor License (Certification #. 6233059853).

  • TFDA, the first-class medical license issued by the Ministry of Health and Welfare.

bottom of page